CN109876039A - Extract from the benzyl carbinol glycosides composition and preparation method thereof of bend pipe broomrape - Google Patents
Extract from the benzyl carbinol glycosides composition and preparation method thereof of bend pipe broomrape Download PDFInfo
- Publication number
- CN109876039A CN109876039A CN201910196256.7A CN201910196256A CN109876039A CN 109876039 A CN109876039 A CN 109876039A CN 201910196256 A CN201910196256 A CN 201910196256A CN 109876039 A CN109876039 A CN 109876039A
- Authority
- CN
- China
- Prior art keywords
- benzyl carbinol
- preparation
- composition
- carbinol glycosides
- ethyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention relates to a kind of pharmaceutically acceptable composition for extracting from Chinese medicine, the benzyl carbinol glycoside compound containing 68-75%, the new Phenylpropanoid Glycosides glucoside (crenatoside) of acteoside (acteoside) and 11-15% including 28-33%.The invention further relates to the preparation method of the composition, comprising extracting and purification step, the extraction step are as follows: with the ethyl alcohol of 45-55% 60-80 DEG C reflux 1.5-2.5 hours；In the purification step, one of column chromatography, described macroreticular resin model HP-20, D-101, HPD-300, DMP-10 and AB-8 are carried out with macroreticular resin, eluting solvent is 30%~50% ethyl alcohol.
Description
Technical field
The present invention relates to Pharmaceutical composition, native compound preparation method and its medical usages.
Background technique
There are 23 kinds known to broomrape platymiscium, it is a kind of to study more only broomrape at present.Its alias is caulis akebiae horse pocket
Bell, CAULIS ARISTOLOCHIAE, broomrape, Du Gencao, rabbit bent stick, mountain maize, Latin literary fame Orobanche coerulescens Steph,
With all herbal medicine.It is sour, bitter, cool in nature, return liver, kidney, large intestine channel, have kidney tonifying, strengthening tendons effect, for control kidney deficiency waist and knee crymodynia,
The diseases such as impotence, spermatorrhea, infantile enteritis, diarrhea.
It is three-level protective endangered species in China although the species have good medical value, it is extensive to its
It is limited using existing, it is necessary to find substitutes for it kind.
Bend pipe broomrape is that Orobanche is annual, biennial or perennial parasitic herbaceous plant, China be distributed mainly on Jilin,
The ground such as the Inner Mongol, Hebei, Shanxi, Shaanxi, Gansu, Qinghai and Xinjiang, resourceful, Yin Qichang parasitizes the root of crops,
Now mostly handled as weeds.Chemical component contained by bend pipe broomrape is mainly benzyl carbinol glycoside compound (Phenylethaniod
Glycosides, PhGs), modern pharmacological studies have shown that having antifatigue, improvement brain tissue circulation, enhancing immune and male sex hormone
Sample effect.
Summary of the invention
An object of the present invention is to provide a kind of benzyl carbinol glycosides composition for extracting from bend pipe broomrape, has centainly
Medicinal and edible value, can be used as drug and functional food uses.
It is a further object of the present invention to provide the preparation method of aforementioned composition, the composition that this method obtains has higher
Benzyl carbinol glycosides content.
It is a further object of the present invention to provide several applications of aforementioned composition.
According to a first aspect of the present invention, the benzyl carbinol that the benzyl carbinol glycosides composition of bend pipe broomrape contains 68-75% is extracted from
Glycosides compound, the new Phenylpropanoid Glycosides glucoside of acteoside (acteoside) and 11-15% including 28-33%
(crenatoside)。
In the second aspect of the present invention, include extraction and purification step to obtain the preparation method of aforementioned composition, it is described
Extraction step are as follows: with the ethyl alcohol of 45-55% 60-80 DEG C reflux 1.5-2.5 hours；In the purification step, macroreticular resin is used
Column chromatography is carried out, one of described macroreticular resin model HP-20, D-101, HPD-300, DMP-10 and AB-8 are eluted molten
Agent is 30%~50% ethyl alcohol.
In a preferred embodiment, in extraction step, extraction time is 2~4 times, and solid-liquid ratio is 1:10~1:15.
Further, in extraction step, with the ethyl alcohol of 50-55% 70-75 DEG C reflux 1.5-2.0 hours；Extraction time
It is 3 times, solid-liquid ratio 1:10.
In a preferred embodiment, before reflow, medicinal material is impregnated into 1~2h.
In a preferred embodiment, in purification step, chromatographic column diameter height ratio 1:5~1:10, preferably 1:8~1:10.
In a preferred embodiment, the ethyl alcohol that eluant, eluent is 30%~50%, elution speed are 1.5~0.5 BV
h-1.It is highly preferred that the ethyl alcohol that eluant, eluent is 45%~50%, elution speed is 1.1~0.9BVh-1.
It is highly preferred that elution volume is 4~7BV.
The invention further relates to a kind of Pharmaceutical compositions, by the aforementioned benzyl carbinol glycosides composition and medicine for extracting from bend pipe broomrape
It is formed with auxiliary material, auxiliary agent.
Benzyl carbinol glycosides composition according to the present invention can be used for treating kidney deficiency waist and knee crymodynia, impotence, spermatorrhea, little Er Chang
The diseases such as inflammation, diarrhea.It is also used as tonifying the kidney and support yang, adjusts the functional food in terms of enterogastric peristalsis.
Present invention firstly provides it is a kind of can with the bend pipe broomrape extract composition of industrialized production with and preparation method thereof,
The content of extractive composition benzyl carbinol glycosides substance with higher has preferable medical value and edible value.
Detailed description of the invention
Fig. 1 is the finger-print obtained according to the method for the present invention；
Fig. 2 shows 9 single reference substance maps；
Fig. 3 is 12 crowdes of bend pipe broomrape active component HPLC finger-print stacking charts.
Specific embodiment
According to the present invention, it extracts from the benzyl carbinol glycosides composition of bend pipe broomrape, main component is benzyl carbinol glycoside chemical combination
Object, total content are 68-75% in mass, and two of them content highest, one is acteosides, reach 28-33%；It is another
Kind is new Phenylpropanoid Glycosides glucoside (crenatoside), is 11-15%.Remaining ingredient includes 2'- acetyl in benzyl carbinol glycoside compound
Base acteoside, Isoacteoside, people from day grass glucoside A (leucosceptoside A), different new Phenylpropanoid Glycosides glucoside
(isocrenatoside), the new glycosides I of bignoniad (campneoside I), the new glycosides II of bignoniad (campneoside II) and
Kankanose etc..In the composition, in addition to benzyl carbinol glycoside compound, remaining ingredient include mannitol, cupreol,
Succinic acid, protocatechuic acid, caffeic acid, beta carotene etc., their total content are no more than 32%.
In preferred preparation method of the invention, benzyl carbinol glycosides composition obtained contains the benzyl carbinol glycosides of 72-75%
Class compound, wherein the new Phenylpropanoid Glycosides glucoside of acteoside and 13-15% including 30-33%.In a preferred embodiment,
In prepared benzyl carbinol glycosides composition, phenylethanoid glycosides, acteoside, new Phenylpropanoid Glycosides salidroside content are up to 75%, 32% respectively
With 15%.
In order to prepare composition according to the present invention, used extraction process are as follows: with 45%~55%, more preferable 50-
55% ethanol solution is Extraction solvent, is heated to reflux bend pipe broomrape, and reflux temperature is suitable for the more preferable 70-75 at 60~80 DEG C
It between DEG C, can flow back 2-4 times, flow back 1.5~2.5 hours every time, it is 1.5-2.0 hours more preferable.Before reflow, feed liquid is used
Than the solvent soaking medicinal material for 1:10~1:15, soaking time can be at 1~2 hour.
In purification step, used condition are as follows: macroreticular resin model be preferably HP-20, D-101, HPD-300,
DMP-10 and AB-8；Chromatographic column diameter height compares for 1:5~1:10, preferably 1:8~1:10；Eluant strength is 30%~50%, excellent
Select 45%~50% ethyl alcohol；Elution speed is 1.5~0.5BVh-1, preferably 1.1~0.9BVh-1；Elution volume be 4~
7BV。
In the present invention, standard finger-print is established for aforementioned composition, specific as follows:
(1) chromatographic condition:
Chromatographic column: octadecylsilane chemically bonded silica chromatographic column；Mobile phase: acetonitrile (A)-phosphoric acid water (B) system gradient is washed
It is de-: 91%B (0min)~76%B (50min)；Testing conditions: DAD detector, wavelength is between 210 nm~800nm；Flow velocity:
0.8~1.2mLmin-1；Column temperature: 20~35 DEG C；Sample volume: 10~20 μ L.
(2) similarity that sample is calculated with similarity evaluation software, obtains finger-print, and similarity is greater than 0.9 and determines
The sample quality to be evaluated meets the requirements.
Determine that 9 peaks are pointed out, similarity is all 0.99 or more using No. 13 peaks as reference peak in 15 shared peaks altogether.It points out
9 peaks be respectively kankanose, the new glycosides II of bignoniad (campneoside II), the new glycosides I of bignoniad, acteoside, different ergot steroid
Glycosides, new Phenylpropanoid Glycosides glucoside (crenatoside), people from day grass glucoside A (leucosceptoside A), 2'- acetyl group acteoside
(2'-acetyl acteoside), different new Phenylpropanoid Glycosides glucoside (isocrenatoside).
Finger-print includes that the retention time at the shared peak in 15 shared peaks is respectively as follows: 8.637,9.567,15.717,
16.163,19.928,20.834,22.050,23.261,26.716,27.517,31.440,32.097,34.328,
36.650 41.474.The relative peak area at 15 shared peaks is respectively 0.049,0.084,0.300,0.334,0.171,
0.048,0.025,9.406,0.495,3.766,0.130,0.161,1.000,0.656,0.157.
Composition of the invention can be used for treating the diseases such as kidney deficiency waist and knee crymodynia, impotence, spermatorrhea, infantile enteritis, diarrhea, also
It can be used as and tonify the kidney and support yang, adjust the functional food in terms of enterogastric peristalsis.
In order to obtain expected curative effect, benzyl carbinol glycosides composition of the invention is preferably with oral administration.For this purpose, this hair
Bright composition can with one or more excipient compositions, to form tablet, pill, pastille, capsule, elixir, suspension, sugar
Slurry, wafer (wafer)) etc. form.This composition and preparation should include at least 0.1% one or more present invention
Compound.
Tablet, pastille, pill, capsule etc. also may include: adhesive, such as tragacanth, Arabic gum, cornstarch or bright
Glue；Excipient, such as Dicalcium Phosphate；Disintegrating agent, such as cornstarch, potato starch, alginic acid；Lubricant, such as magnesium stearate；With
Such as sucrose, fructose, lactose or aspartame, or aromatic such as peppermint, wintergreen or cherry flavor enhancement can be added in sweetener.When
When unit dosage form is capsule, in addition to above type of material, it also may include liquid-carrier such as vegetable oil or polyethylene glycol.It is various
The shape (physical form) for changing solid unit dosage forms as coating or in other ways may be present in other materials.For example,
Tablet, pill or capsule can be coated with gelatin, wax, shellac, sugar etc..Syrup or elixir may include the sucrose or fruit as sweetener
Sugar.
In a preferred embodiment of the invention, the excipient used is microcrystalline cellulose, cyclodextrin or sucrose.One
It is in a embodiment, the composition of proposition and microcrystalline cellulose is appropriate, it mixes, with 95% appropriate amount of ethanol of 5% PVP K30
Softwood processed is pelletized, dry, whole grain, and 7% low-substituted hydroxypropyl cellulose is added and 0.5% magnesium stearate mixes, tabletting, packet film
Piece is made in clothing., can be by benzyl carbinol glycosides composition and excipient of the invention with the ratio of 1:1~5 in the present invention, being made can
Oral pharmaceutical composition.
In general, suitable dosage can be 1~200mg/kg/ days, such as from about 2~100mg/kg body weight/day, and such as from about 5
~50mg/kg receptor body weight/day.
The preparation of 1 phenylethanoid glycosides composition of embodiment
Bend pipe broomrape medicinal powder is weighed, the ethanol solution of 10 times of amounts 50% is added, after impregnating 1.5 hours, 70 DEG C next time
Stream extracts 2 hours, extracts altogether three times, combined extract, and concentration obtains medicinal extract.
Purified with DMP-10 macroreticular resin, sample concentration 0.05gmL-1, loading flow velocity 1.5~2BV h-1,
Chromatographic column diameter height ratio 1:8, eluant, eluent is 45% ethyl alcohol；Elution speed 1.1BVh-1；Elution volume (4~7BV).It obtains
In composition, phenylethanoid glycosides, acteoside, new Phenylpropanoid Glycosides salidroside content are respectively 75.08%, 33.02% and 12.49%.
The foundation of 2 composition standard fingerprint of embodiment
1. the preparation of test solution
Precision weighs the resulting composition 0.2g of embodiment 1 in stuffed conical flask, and the ethanol solution of calculation amount is added
25mL, ultrasonic extraction, filtration, take subsequent filtrate with the filtration of 0.45 μm of miillpore filter to get.
2. the preparation of reference substance solution
It is accurate respectively to weigh the kankanose being dried under reduced pressure to constant weight, campneoside II, campneoside I,
Acteoside, isoacteoside, crenatoside, leucosceptoside A, 2'-acetyl acteoside,
Isocrenatoside reference substance is appropriate, and methanol dissolution is configured to certain density reference substance solution, then accurate respectively to draw
Above-mentioned reference substance is in right amount into 10mL volumetric flask, and methanol constant volume is made into certain density mixed reference substance solution, in 4 DEG C of ice
It is saved backup in case.
3. chromatographic condition
Chromatographic column: octadecylsilane chemically bonded silica chromatographic column；Mobile phase: acetonitrile (A)-phosphoric acid water (B) system gradient is washed
It is de-: 91%B (0min)~76%B (50min)；Testing conditions: DAD detector, wavelength is between 210 nm~800nm；Flow velocity:
0.8~1.2mLmin-1；Column temperature: 20~35 DEG C；Sample volume: 10~20 μ L.
4. the label at shared peak
The phenylethanoid glycosides of 12 batches of bend pipe broomrapes are prepared according to aforementioned bend pipe broomrape active component process for extracting, separating and purifying,
According to the above-mentioned operating method having built up, sample introduction is analyzed respectively, obtains the HPLC standard finger-print of active component, and determine
15 shared peaks form common pattern.Wherein No. 13 peaks are referring to peak (S), and relative retention time and relative peak area are
1.000, other peaks calculate relative retention time and relative peak area in contrast, are shown in Table 1.
Table 1 shares the relative retention time and relative peak area at peak
5. the foundation of finger-print
12 parts of sample maps of above-mentioned acquisition are imported in similarity evaluation software, similarity is calculated with average method, is obtained
Finger-print (Fig. 1).Reference substance and S1 trace analysis identify 1,4,7,8,9,10,12,13, No. 14 peak as a result such as Fig. 2.
Using aforementioned condition, finger-print is obtained, it includes 15 shared peaks, retention time and relative peak area difference
Are as follows: 8.637,0.049；15.717 0.300；16.163 0.334；19.928 0.171；20.834 0.048；22.050,
0.025；23.261 9.406；26.716 0.495；27.517 3.766；31.440 0.130；32.097 0.161；
34.328 1.000；36.650 0.656；41.474 0.157.Simultaneously by the reference substance solution prepared with the same terms into
Sample identifies 9 in 15 shared peaks, this 9 peaks are corresponding with peak number in finger-print as follows:
No. 1 peak is kankanose
No. 4 peaks are campneoside II
No. 7 peaks are campneoside I
No. 8 peaks are acteoside
No. 9 peaks are isoacteoside
No. 10 peaks are crenatoside
No. 12 peaks are leucosceptoside A
No. 13 peaks are 2'-acetyl acteoside
No. 14 peaks are isocrenatoside
6. methodological study
(1) precision is investigated: take same test solution, continuous sample introduction 6 times, and with No. 13 peak 2'-acetyl
Acteoside is reference peak, calculates the RSD of each shared peak relative retention time and relative peak area, the results showed that each chromatographic peak
RSD≤0.09% of relative retention time, RSD≤2.91% of relative peak area meet the requirement of finger-print.
(2) repetitive test: taking 6 parts of same batch of sample, test solution be made and is analyzed, with No. 13 peak 2'-
Acetyl acteoside is reference peak, calculates the RSD of each shared peak relative retention time and relative peak area, the results showed that
RSD≤0.87% of each chromatographic peak relative retention time, RSD≤2.92% of relative peak area show analysis method repeatability
Well.
(3) stability test: taking with a collection of test solution, respectively 0,2,4,8,12, sample introduction for 24 hours, with No. 13 peaks
2'-acetyl acteoside is reference peak, calculates the RSD of each shared peak relative retention time and relative peak area, as a result table
RSD≤0.16% of bright each chromatographic peak relative retention time, RSD≤2.94% of relative peak area show that test solution exists
Stablize in for 24 hours.
7. similarity evaluation
" the traditional Chinese medicine fingerprint similarity calculation software for being used to generate common pattern formulated with Chinese Pharmacopoeia Commission
2004A editions ", 12 batch bend pipe broomrape active component spectrum datas are imported, control map are generated, through Supplements, chromatographic peak
Matching calculates similarity with average, obtains the similarity result of 12 batch bend pipe broomrape active components, similarity is all 0.99
More than, 2 are shown in Table, each batch sample HPLC map stacking chart sees Fig. 3.
2 standard fingerprint figure similarity result of table
Test of 3 composition of embodiment to white mouse immunization
Composition made from embodiment 1 is made into aqueous solution, mouse is awarded with the amount of drug net content 30mg/kg, is observed
Every immune function.As a result: spleen and thymic weight increase to 125 ± 10 and 47 from 73 ± 10 and 31 ± 6mg/kg ±
6mg/kg；Abdominal cavity macrophage phagocytosis increases to 73 ± 3% from 51 ± 5%；Hemolysin and hemolysis plaque value are respectively from 141 ± 43 Hes
0.05 ± 0.1 increase is 345 ± 52 and 0.18 ± 0.01, and cGMP content is reduced to 37 ± 5 from 59 ± 10 (pmol/ml)；Make late
The hypersensitivity of hair property increases power 0.82 ± 0.12 from 0.54 ± 0.15 (mm).Show body of the water soluble ingredient to mouse of the product
Liquid and cellular immunity have humidification.
4 composition of embodiment tests the effect of digestive system
Influence to mouse small intestine pushing function: the female mice of 35~43g of weight, medical fluid and distilled water comparison liquid used
Charcoal end is mixed into before administration (dosage is the 5% of medical fluid).By 0.5ml/ kg respectively for examination after the jejunitas water supply of mouse 14 hours
Liquid is put to death after twenty minutes.It cuts open the belly and takes out small intestine measurement.Using pylorus to charcoal footline into farthest as advance rate, pylorus to ileocaecal sphineter
For overall length, the former is advance rate divided by the latter.Broomrape each group can significantly improve mouse small intestine advance rate, it was demonstrated that the medicine can enhance intestines
It wriggles, plays the role of improving myenteron motor function.
Inhibit the antagonism of defecation to atropine: 42 ± 39 male mice of weight and weight 46 ± 4g female mice being taken to press
Weight is randomly divided into 4 groups, half male and half female.After jejunitas water supply 16 hours, simple water supply group is by 0.15ml/10g weight ig respectively for examination
Liquid.It records atropine time, each test liquid time and mouse and first red excrement time is discharged, calculate the defaecation time.As a result
Show that 0.025% atropine has apparent inhibition defecation to mouse, broomrape can be effective against this inhibition of atropine
Defecation, antagonistic intensity is compared with metoclopramide without significant difference (P > 0.47).
The present invention establishes the extraction and purification process of active component in bend pipe broomrape (the total glycosides of bend pipe broomrape), and establishes effective
Quality of the standard finger-print at position for bend pipe broomrape active component controls, and studies its application in disease treatment.
The preparation method of foundation can be effectively removed the larger and lesser impurity of polarity in bend pipe broomrape；The mark for the active component established
Quasi- finger-print can comprehensively, steadily evaluate the quality of active component, guarantee the phenylethanoid glycosides quality of every a collection of technique preparation
It is uniform, stable, controllable.
Design of the invention is described in conjunction with specific embodiments above.Part details disclosed by these embodiments is not
Make sense into limitation of the present invention, all tune that those skilled in the art do these technical details after by enlightenment of the invention
Whole, replacement, modification and optimization are all covered by the restriction of patent claims book and its equivalent replacement.
Claims (10)
1. extracting from the benzyl carbinol glycosides composition of bend pipe broomrape, it is characterised in that the benzyl carbinol glycoside compound containing 68-75%,
The new Phenylpropanoid Glycosides glucoside of acteoside and 11-15% including 28-33%.
2. benzyl carbinol glycosides composition as described in claim 1, it is characterised in that the benzyl carbinol glycoside chemical combination containing 72-75%
Object, wherein the new Phenylpropanoid Glycosides glucoside of acteoside and 13-15% including 30-33%.
3. the preparation method of benzyl carbinol glycosides composition as described in claim 1, comprising extraction and purification step, the extraction step
Suddenly are as follows: with the ethyl alcohol of 45-55% 60-80 DEG C reflux 1.5-2.5 hours；In the purification step, column is carried out with macroreticular resin
Chromatography, one of described macroreticular resin model HP-20, D-101, HPD-300, DMP-10 and AB-8, eluting solvent is
30%~50% ethyl alcohol.
4. the preparation method of benzyl carbinol glycosides composition as claimed in claim 3, which is characterized in that in extraction step, extract secondary
Number is 2~4 times, and solid-liquid ratio is 1:10~1:15.
5. the preparation method of benzyl carbinol glycosides composition as claimed in claim 4, which is characterized in that in extraction step, use 50-
55% ethyl alcohol 70-75 DEG C reflux 1.5-2.0 hours；Extraction time is 3 times, solid-liquid ratio 1:10.
6. the preparation method of benzyl carbinol glycosides composition as claimed in claim 3, which is characterized in that before reflow, by medicinal material
Impregnate 1~2h.
7. the preparation method of benzyl carbinol glycosides composition as claimed in claim 3, which is characterized in that in the purification step, layer
Analyse column diameter height ratio 1:5~1:10, preferably 1:8~1:10.
8. the preparation method of benzyl carbinol glycosides composition as claimed in claim 3, which is characterized in that eluant, eluent is 30%~50%
Ethyl alcohol, elution speed be 1.5~0.5BVh-1。
9. the preparation method of benzyl carbinol glycosides composition as claimed in claim 8, which is characterized in that eluant, eluent is 45%~50%
Ethyl alcohol, elution speed be 1.1~0.9BVh-1。
10. such as the preparation method of the described in any item benzyl carbinol glycosides compositions of claim 3-9, which is characterized in that elution volume
For 4~7BV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018109844206 | 2018-08-28 | ||
| CN201810984420 | 2018-08-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109876039A true CN109876039A (en) | 2019-06-14 |
| CN109876039B CN109876039B (en) | 2021-10-12 |
Family
ID=66458386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910196256.7A Active CN109876039B (en) | 2018-08-28 | 2019-03-15 | Phenylethanoid glycoside composition extracted from oroxylum bengelliforme and preparation method thereof |
| CN201910196353.6A Active CN109758499B (en) | 2018-08-28 | 2019-03-15 | Application of herba Orobanches extract in preparing medicine for treating diabetes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910196353.6A Active CN109758499B (en) | 2018-08-28 | 2019-03-15 | Application of herba Orobanches extract in preparing medicine for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN109876039B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411753A (en) * | 2008-12-04 | 2009-04-22 | 闫明 | Broomrape extract, broomrape total glycosides, broomrape polysaccharide as well as preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283854A (en) * | 2011-06-23 | 2011-12-21 | 上海中医药大学 | Application of ergot sterioside |
-
2019
- 2019-03-15 CN CN201910196256.7A patent/CN109876039B/en active Active
- 2019-03-15 CN CN201910196353.6A patent/CN109758499B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411753A (en) * | 2008-12-04 | 2009-04-22 | 闫明 | Broomrape extract, broomrape total glycosides, broomrape polysaccharide as well as preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杨美珍等: "弯管列当的化学成分研究", 《中草药》 * |
| 白贞芳等: "弯管列当提取物的抗氧化活性 ", 《中国实验方剂学杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109758499B (en) | 2021-10-08 |
| CN109876039B (en) | 2021-10-12 |
| CN109758499A (en) | 2019-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | A review on traditional uses, phytochemistry, pharmacology, pharmacokinetics and toxicology of the genus Peganum | |
| US9770479B2 (en) | Extract of Rehmannia glutinasa Libosch for reducing blood sugar, reducing blood fat, treating leukemia, and preparation method and uses thereof | |
| CA2659442C (en) | Cinnamomi and poria composition and uses thereof | |
| CN101342229B (en) | Composition of Canton love-pea vine extract, preparation method and pharmaceutical use | |
| US11458087B2 (en) | Method of isolating cannabidiol from Cannabis plant and use thereof | |
| CN108064160B (en) | A pharmaceutical composition containing extract or fraction of mixture of peony root bark, dahurian angelica root and bupleurum root as active ingredient | |
| CN102228506A (en) | Composition of malaytea scurfpea extract as well as preparation method and use thereof | |
| JPH01226824A (en) | Metabolic promoter for urea nitrogen | |
| Nigam et al. | Pharmacognostic study, characterization of marker compounds and pharmacological review of aerial parts of hygrophila auriculata (schumach.) heine | |
| CN109876039A (en) | Extract from the benzyl carbinol glycosides composition and preparation method thereof of bend pipe broomrape | |
| CN109248188A (en) | A kind of preparation method and applications of goldspink root extract | |
| CN107412462B (en) | Preparation method of Huanglong cough and asthma capsule | |
| KR100633096B1 (en) | Blood vessel relaxational agent containing decursin or decursinol angelate | |
| CN101816702B (en) | Lung cancer preventing and treating composition extracted from selfheal and/or garden orache and application thereof in preparation of lung cancer preventing and treating medicine | |
| CN112386630A (en) | Brain-strengthening and intelligence-improving composition and preparation method and medical application thereof | |
| CN114588187B (en) | Traditional Chinese medicine total flavone extract for treating cataract, and composition, preparation method and medical application thereof | |
| CN104983725B (en) | A kind of pharmaceutical composition with anti-dysmenorrhoea effect and preparation method thereof | |
| CN112274588B (en) | Preparation method and application of extract of plant of genus Convolvulus | |
| CN110448622B (en) | Medicine for treating heat type cold and preparation method and application thereof | |
| CN102526154B (en) | Method for preparing antitumor medicine burdock root extractive | |
| KR20040079265A (en) | Blood vessel relaxational agent containing decursin or decursinol angelate for the prevention or treatment of blood vessel disease | |
| Gao et al. | Advances in Phytochemistry and Modern Pharmacology of Saposhnikovia Divaricata (Turcz.) Schischk | |
| CN113229498A (en) | Medicinal and edible composition formula conducive to blood pressure reduction and preparation process thereof | |
| KR20150138122A (en) | Improving Vascular Disorder Related Cholesterol Metabolism Food Composition Containing Solidago Virgaurea Extract and Method for Preparing the Same | |
| Suloev et al. | Isolation of individual flavonoids from Solidago canadensis L |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |